Food and Drug Administration
Compounding pharmacies are in the crosshairs of the Food and Drug Administration. Subjecting this time-honored tradition to more government regulation will not make it safer. In fact, it will increase cost of the healthcare for folks who use compounded medications, further restrict our health freedom, and diminish competition with the big pharmaceutical companies.
For years, the pharmaceutical industry has been searching for new ways to get its drugs to market faster and with fewer pre-approval testing and clinical trial requirements. And it appears that the industry has made significant headway with the 2012 passage of the Food and Drug Administration Safety and Innovation Act (FDASIA), which allows some untested drugs to be rushed to market very quickly under the designation of being a "breakthrough therapy."